Spots Global Cancer Trial Database for Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Official Title: Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors: a Single-arm, Non-randomized, Single-center Phase II Trial

Study ID: NCT04010071

Conditions

Hepatobiliary Neoplasm

Liver Neoplasm

Biliary Tract Neoplasms

Interventions

axitinib plus toripalimab

Study Description

Brief Summary: The investigators design a phase II clinical study to explore the efficacy and safety of axitinib plus toripalimab as a second-line treatment in patients with hepatobiliary malignant tumors and to analyze potential biomarkers of therapeutic response.

Detailed Description: This phase II trial is a single-arm, non-randomized and single-center clinical study. It is estimated that 60 patients who met the study criteria will be enrolled in PUMCH and treated with axitinib plus toripalimab. The investigators will follow up and collect subjects' data each month to evaluate the efficacy and safety of treatment, including overall survival and time to progression, until disease progression or death. Histopathology and multi-omics data analysis will be used to explore potential biomarkers of treatment response. Study Type: Interventional. Masking: Open Label.